Log In Sign up
The largest database of trusted experimental protocols

Clone 2

Manufactured by BioXCell
Visit Supplier

The Clone 2.43 is a laboratory equipment designed for cell culture applications. It provides a controlled environment for the growth and maintenance of cells. The product's core function is to enable consistent and reliable cell culture conditions.

Automatically generated - may contain errors

Lab products found in correlation

Clone gk1, by BioXCell (10 mentions) Clone 2a3, by BioXCell (3 mentions) Clone ltf 2, by BioXCell (3 mentions) Clone afs98, by BioXCell (3 mentions) Clone cxcr3 173, by BioXCell (2 mentions) Clone rmp1 14, by BioXCell (2 mentions) Ifnγ clone xmg1.2, by BioXCell (2 mentions) Clone yigif74 1g7, by BioXCell (2 mentions) Clone 1a8, by BioXCell (2 mentions) Ltf 2, by BioXCell (1 mentions) Fingolimod fty720, by Selleck Chemicals (1 mentions) Bp0090, by BioXCell (1 mentions) S1200, by Selleck Chemicals (1 mentions) Clone pk136, by BioXCell (1 mentions) C57bl 6 mice, by Charles River Laboratories (1 mentions) Female balb c mice, by Jackson ImmunoResearch (1 mentions) Wild type c57bl 6 mice, by Jackson ImmunoResearch (1 mentions) Armenian hamster igg, by BioXCell (1 mentions) Anti cd8a, by BioXCell (1 mentions) Anti pd 1, by BioXCell (1 mentions)

24 protocols using clone 2

1

T Cell Depletion and Recruitment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD8+ and CD4+ T cell depletions were accomplished with mouse anti-CD8 (BioXcell, Clone 2.43) and mouse anti-CD4 (BioXcell, Clone GK1.5), respectively. Depleting antibodies were given via i.p. injection at 200 μg/injection every two days starting on D6. For T cell recruitment studies, mouse anti-CXCR3 antibody (BioXcell, Clone CXCR3-173) was administered i.p, at 200 μg/injection. Prevention of T cell LN egress was performed with fingolimod hydrochloride (FTY720; Cayman, 10006292) administered i.p. every other day at 2 mg/kg. All antibody experiments utilized isotype controls (BioXcell, Clone 2A3 or LTF-2).
Lim R.J., Salehi-Rad R., Tran L.M., Oh M.S., Dumitras C., Crosson W.P., Li R., Patel T.S., Man S., Yean C.E., Abascal J., Huang Z., Ong S.L., Krysan K., Dubinett S.M, & Liu B. (2024). CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell Reports Medicine, 5(4), 101479.
+ Open protocol
+ Expand
2

Combination Immunotherapy with CpG and Anti-OX40

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
CpG (50 μg; 1826 from Integrated DNA Technologies) and anti-OX40 (20 μg; OX86 clone, European Collection of Cell Cultures, harvested and isolated from immunodeficient mice [26 (link)]) in 60μL PBS were injected IT with a 29½ gauge insulin syringe on days 0, 2, and 4 after randomization. Anti-CTLA-4 (200 μg in 100μL PBS; clone 9D9 from Bristol Myers Squibb) was injected intraperitoneally (IP) with a 26 gauge needle on days 2, 5, and 8. Anti-CD4 (400 μg; clone GK1.5 from Bio X Cell) and anti-CD8 (400 μg; clone 2.43 from Bio X Cell) in 200μL PBS were injected IP on days − 1, 6, and 13 for T cell depletion experiments [27 ].
The antibodies used for flow cytometry analysis are listed in Table S1.
Pieper A.A., Spiegelman D.V., Felder M.A., Feils A.S., Tsarovsky N.W., Zaborek J., Morris Z.S., Erbe A.K., Rakhmilevich A.L, & Sondel P.M. (2023). Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist. Cancer Immunology, Immunotherapy, 72(7), 2459-2471.
+ Open protocol
+ Expand
3

Influenza Virus Challenge Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
For PR8 challenge studies, mice were inoculated with 500 PFU of PR8 by intranasal (IN) instillation in 50ul PBS applied to the nares under isoflurane anesthesia, and were humanely euthanized at 6 days post infection. Lung tissues for viral titration (left lobe) were frozen at −80°C. To assess the role of CD4 T cells and CD8 T cells in protective immunity, mice were administered 200 μg of anti-CD4 (Bio X Cell, Clone: GK1.5) or CD8 T cells (Bio X Cell; Clone 2.43) intravenously and intranasally at days -5. -3, -1 and 1, 3, and 5 relative to challenge with influenza A virus. Fingolimod (FTY720, Selleck Chemicals) was administered to mice by intravenous injection at a dose of 5mg/kg bodyweight on days. -3, -1 and 1, 3, and 5 relative to challenge with influenza virus.
Kingstad-Bakke B., Toy R., Lee W., Pradhan P., Vogel G., Marinaik C.B., Larsen A., Gates D., Luu T., Pandey B., Kawaoka Y., Roy K, & Suresh M. (2021). Polymeric Pathogen-Like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus. Frontiers in Immunology, 11, 559382.
+ Open protocol
+ Expand
4

Depletion of CD8+ and CD25+ Cells in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the depletion of CD8+ cells, Atg5+/+ and Atg5flox/flox mice were treated with an anti-CD8a (0.2 mg/mouse; Bio X Cell, clone 2.43) depleting antibody or a control IgG (0.2 mg/mouse; Bio X Cell, BP0090) intraperitoneally (i.p.) in 0.1 ml PBS at Days -1, +1, +7 and +15 pre- and post-tumor cell implantation. For the depletion of CD25+ cells, Atg5+/+ mice were treated with anti-CD25 depleting antibody (0.25 mg/mouse; Bio X Cell, clone PC-61.5.3) or a control IgG (0.25 mg/mouse; Sigma, I4131) intraperitoneally at Days -1, +3, +10 and +17 relative to tumor cell implantation. MST cells (5x104) were orthotopically implanted in the SMGs of mice at Day 0.
Cao S., Hung Y.W., Wang Y.C., Chung Y., Qi Y., Ouyang C., Zhong X., Hu W., Coblentz A., Maghami E., Sun Z., Lin H.H, & Ann D.K. (2022). Glutamine is essential for overcoming the immunosuppressive microenvironment in malignant salivary gland tumors. Theranostics, 12(13), 6038-6056.
+ Open protocol
+ Expand
5

Establishment of Orthotopic Mammary Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
To establish orthotopic models, either 66cl4-shMYC-NC/1/3 or 4T1-MYC-vec/oe cells in 50 µL of DMEM medium were injected into the fourth mammary gland of 6-week-old female BALB/c or NSG mice (66cl4: 1×106 cells; 4T1: 5×105 cells). For CD8+ T cell depletion experiments, 6-week-old female BALB/c mice were treated with rat IgG2b (BioXCell, clone LTF-2, 100 µg injected intraperitoneally on day 1, followed by 50 µg on day 3 and 50 µg weekly for the remainder of the experiment) or anti-mouse CD8a (BioXCell, clone 2.43, 100 µg injected intraperitoneally on day 1, followed by 50 µg on day 3 and 50 µg weekly for the remainder of the experiment). For in vivo combination therapy, mice were treated with diluent or decitabine alone (S1200, Selleck, 0.8 mg/kg, intraperitoneal injection, every day) or in combination with isotype IgG (BioXcell, clone 2A3, 100 µg injected intraperitoneally, on days 3, 7, 10, 14) or anti-PD-1 antibody (BioXcell, clone RMP1-14, 100 µg injected intraperitoneally, on days 3, 7, 10, 14).
Tumor growth was measured 2–3 times per week using calipers. The primary tumors were harvested for analysis once they reached a 3–5 week time point or a volume of 1 or 2 cm3 using the formula: volume = (width2 ×length)/2. Mice were humanely sacrificed after measurement. For experimental accuracy, these data were also included.
Wu S.Y., Xiao Y., Wei J.L., Xu X.E., Jin X., Hu X., Li D.Q., Jiang Y.Z, & Shao Z.M. (2021). MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. Journal for Immunotherapy of Cancer, 9(7), e002528.
+ Open protocol
+ Expand
6

Immune Cell Depletion and Cytokine Neutralization

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Depletions of immune cells were done using antibodies against CD8α (clone 2.43, BioXCell 400 ug i.p. twice weekly), NK1.1 (clone PK136, BioXCell, 400 ug i.p. twice weekly), Ly6g (clone 1A8, BioXCell, 400 ug i.p. twice weekly) or CSF1R (clone AFS98, BioXCell, 300 ug i.p. every other day) as previously described26 (link). Cytokine neutralization was done using i.p. treatments with 200 ug of antibodies against IFN-γ (clone XMG1.2, BioXCell), IL1β (clone B122, BioXCell) and IL18 (clone YIGIF74-1G7, BioXCell) every other day. All depletion antibodies dosing was initiated one day before i.t. treatment and continued till atleast 1 month after treatment.
Agarwal Y., Milling L.E., Chang J.Y., Santollani L., Sheen A., Lutz E.A., Tabet A., Stinson J., Ni K., Rodrigues K.A., Moyer T.J., Melo M.B., Irvine D.J, & Wittrup K.D. (2022). Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nature biomedical engineering, 6(2), 129-143.
+ Open protocol
+ Expand
7

Cellular Subset Depletion and ICAM1 Blockade

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cellular subsets were depleted by administering depleting antibody i.p. twice weekly beginning 1 day prior to therapy, as follows: CD8 T cells with anti-CD8α (200 µg/mouse, clone 2.43, BioXCell) and NK cells with anti-NK1.1 (250 µg/mouse, clone PK136, BioXCell). For ICAM1 blockade, mice were injected intraperitoneally with α-ICAM1 (200 µg/mouse; clone YN1/1.7.4, BioXcell) twice per week.
Bai X., Guo Z.Q., Zhang Y.P., Fan Z.Z., Liu L.J., Liu L., Long L.L., Ma S.C., Wang J., Fang Y., Tang X.R., Zeng Y.J., Pan X., Wu D.H, & Dong Z.Y. (2023). CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nature Communications, 14, 1247.
+ Open protocol
+ Expand
8

Tumor Engraftment and Antibody Treatments

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
For tumor engraftment, 105 B16, or 105 MC38 tumor cells were injected subcutaneously in 100μl PBS. Tumors were measured via caliper every 2–3 days post tumor engraftment with or without the indicated treatments and tumor volume was calculated by volume = (length × width2)/2. For antibodybased treatment, tumor-bearing mice were i.p. treated with α-CD4 antibody (200 μg per injection, clone GK1.5, BioXcell) and α-CD8 antibody (200 μg per injection, clone 2.43, BioXcell) every three days from day 7 post tumor implantation, or α-CD36 antibody (200 μg per injection, clone CRF D2717 (Wang et al., 2020 (link))) every two days from day 7 post tumor implantation.
Xu S., Chaudhary O., Rodríguez-Morales P., Sun X., Chen D., Zappasodi R., Xu Z., Pinto A.F., Williams A., Schulze I., Farsakoglu Y., Varanasi S.K., Low J.S., Tang W., Wang H., McDonald B., Tripple V., Downes M., Evans R.M., Abumrad N.A., Merghoub T., Wolchok J.D., Shokhirev M.N., Ho P.C., Witztum J.L., Emu B., Cui G, & Kaech S.M. (2021). Uptake of oxidized lipids from the tumor microenvironment by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8 T cells. Immunity, 54(7), 1561-1577.e7.
+ Open protocol
+ Expand
9

Immunotherapy of Localized Melanoma

Check if the same lab product or an alternative is used in the 5 most similar protocols
6 week old female C57BL/6 mice were obtained from Charles River NCI colony (Wilmington, MA). Each mouse was intradermally implanted with B16F10 cells on the left (local, 250,000 cells) and right (distant, 100,000 cells) shoulders. At 8 days post-implantation, the test compound was intratumorally injected to only the left (local) tumor, while the right (distant) tumor was left untreated. Unless otherwise specified, the test compound was given every 3 days for 3 doses. Burden of both local and distant tumors in mice were measured with Vernier Caliper every 1-2 days, and tumor volume was calculated by V = 0.5 x length x width2. Survival was also monitored. Mice were sacrificed when total tumor burden exceeded 2000 mm3. For the study that combined intratumoral treatment with immune checkpoint inhibitors, a cocktail of PD-1 Ab (200 μg/mouse) and CTLA-4 Ab (100 μg/mouse) was given intraperitoneally on the same day (three doses every three days) as intratumoral treatment of our test compounds.
To confirm that the treatment efficacy was immune-mediated, mice treated with AIRISE-02 were injected intraperitoneally with CD8 antibody (200 μg/mouse; clone 2.43, BioXcell), starting one day before the first intratumoral treatment and continuing twice a week throughout the entire study.
Ngamcherdtrakul W., Reda M., Nelson M.A., Wang R., Zaidan H.Y., Bejan D.S., Hoang N.H., Lane R.S., Luoh S.W., Leachman S.A., Mills G.B., Gray J.W., Lund A.W, & Yantasee W. (2021). In situ tumor vaccination with nanoparticle co-delivering CpG and STAT3 siRNA to effectively induce whole-body antitumor immune response.. Advanced materials (Deerfield Beach, Fla.), 33(31), e2100628.
+ Open protocol
+ Expand
10

4T1 Mammary Tumor Induction and Metastasis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female BALB/c mice aged 6–8 weeks were purchased from Jackson Laboratory. To induce the 4T1 orthotopic mammary tumor, 5 × 105 4T1 cells were injected subcutaneously (s.c.) in the abdominal mammary gland and mice were euthanized at indicated times for analysis or monitored for survival. The volume of tumors was calculated as V = L× W2/2, where L and W stand for tumor length and width, respectively. For the lung metastasis model of 4T1, 2 × 105 cells were intravenously infused through the tail vein and mice were sacrificed on d 18 for analysis. For T cell depletion, 4T1 tumor-bearing mice were given anti-mouse CD8α antibody (100 μg/mouse, Clone 2.43, BioXcell) or anti-mouse CD4 antibody (250 μg/mouse, Clone GK1.5, BioXcell) at indicated times. All animal experiments were performed in accordance with National Institutes of Health guidelines for housing and care of laboratory animals after protocol (protocol Number 0701-569A) approved by IACUC at Weill Cornell Medicine.
Song M., Wang C., Wang H., Zhang T., Li J., Benezra R., Chouchane L., Sun Y.H., Cui X.G, & Ma X. (2020). Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response. Oncoimmunology, 9(1), 1746148.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!